Life Science Success

Send us a textIn this episode of Life Science Success my guest is Alex Chen.  Alex is the President of Overseas Operations at uBriGene Biosciences Inc.   He has diversified experience, having worked in various industries such as mining, real estate, and investment banking before joining uBriGene Biosciences Inc. uBriGene Biosciences Inc. is a biotech company that provides services ranging from upstream to downstream, including QC testing The company is focused on innovation and utilizes the most up-to-date technologies to provide cost-effective and quality products uBriGene Biosciences Inc. has sites in the US and China, and its core competency is research and development The company aims to be a partner with its clients and grow with them uBriGene Biosciences Inc. has over 500 employees globally and has raised $100 million to date

Send us a textIn this episode my guest is Jason Bock PhD.  Jason is the CEO of CTMC / A joint venture between Resilience and MD Anderson Cancer Center. Jason Bock has been in biotech and biopharma for over 20 years, mostly in Biologics development. He founded Ctmc, a technology platform to industrialize cell therapies and bring them into the MD Anderson Clinic. Ctmc is a joint venture between MD Anderson and National Resilience. Ctmc partners with preclinical biotech, MD Anderson faculty, and Factus to provide a capital-efficient model to bring impactful single dose curative treatments to patients. Ctmc has filed three INDs in the first six months since it spun off on novel cell therapies brought into the clinic. Ctmc has progressed on the seven clinical studies that it supports. Ctmc recently announced that it was the recipient of a $9.1 million grant to help develop cell therapy platforms and improved ways of making these cell therapies. Jason is inspired by the patients and patient-centricity. He is concerned about the challenges, logistical and manufacturing challenges with autologous cell therapy. What excites him is the potential to transform healthcare and be single-dose curative treatments.

Send us a textIn this episode of Life Science Success my guest is Benedicta Durcan, CEO of Afrobodies. Her work experience has been in complex industries and environments spanning 12 years in Private Sector globally and 8 years in Public Sector in South Africa. I am an Upstream Oil & Gas and Maritime industry Specialist. I am an innovator and contributor in the field of STEM. Benedicta Durcan is the co-founder and CEO of Afro Body, a biotechnology company in South Africa that produces biological products for global consumption, including novel antibodies. Benedicta's background is in chemical engineering, and she has worked in the oil and gas and energy sectors before starting Afro Body with co-founder Dr. Peter Durkin. Afro Body's antibodies are recombinant alpaca antibodies used in life science research, diagnostics, and therapeutics for various diseases. Benedicta's role involves stakeholder management and engagement, raising initial grant funding, building a team, finding collaborators and partnerships, and expanding the company's global reach. Companies and researchers come to Afro Body for custom antibodies to study specific proteins, detect or test for the presence of molecules or bacteria, or develop treatments for diseases. Benedicta is inspired by the passing it on philosophy and believes in leaving a legacy for her children. Benedicta is concerned about the geo policies, global economics, and competing priorities that exacerbate inequalities, particularly in access to lifesaving medicine. Benedicta is excited about traveling and continually expanding her world and perspective.

Send us a textIn this episode of Life Science Success my guest is Jason Mundin, MBA who is the CEO of Ubiquigent.  Jason has over 30 years’ experience in the pharmaceutical and biotechnology industries. He joined Ubiquigent in 2015 as Commercial Director, becoming Managing Director in 2018 and CEO in 2021.  Jason Mundin is the CEO of Ubiquigent, a biotech company that focuses on drug discovery They have taken the company from a loss-making biotech to a profitable one. They are now focused on becoming a drug discovery-focused therapeutics company. They are actively engaged in securing inward investment. They are concerned about the state of funding for the life sciences industry. They are excited about the potential of their programs and the value they can bring to the industry. They believe that innovation is necessary due to limited resources and are constantly looking for ways to be innovative. They are excited to attend conferences and connect with people who are interested in their work.

Send us a textIn this episode of the Life Science Success Podcast my guest is Pavel Printsev.  Pavel is the Director of Business Development at Bridge Biotherapeutics. Prior to joining Bridge in early 2021 he was working at a South Korean VC firm. Pavel’s academic background is in Organic Chemistry and worked as a Research Scientist for several years. Since then, he has been active in advancing scientific development through global partnership, collaboration and investment between South Korea and the rest of the world.   Bridge Biotherapeutics is a small to mid-size Biotherapeutics company founded in 2015. They have clinical-stage assets in nonsmall cell lung cancer, ulcerative colitis, and idiopathic pulmonary fibrosis. They also acquired a next-generation biosensor detection company, which is a thousand times more sensitive than the current commercial ECL biosensor device. Bridge Biotherapeutics is focused on maximizing resources and following the path where they see the most opportunity. Pavel Printsev is inspired by people who have become masters in their respective fields and are dedicated, motivated, ambitious, and do not give up. Concerns include the gap in research and unmet medical needs for indications that may not be profitable. Pavel is excited about the advancements in AI and deep learning, gene editing, and precision medicine.

Send us a textIn this episode of Life Science Success, my guest is David Baram.  David Baram is the co-founder and CEO of Emendo Biotherapeutics. David has taken Emendo from the pre-seed stage through multiple financing rounds and a successful acquisition in 2020. Don Davis, PhD, MBA interviews David Baram, PhD, CEO of Emendo Biotherapeautics Mendo is focused on developing gene editing therapies for rare and prevalent diseases, including cardiovascular diseases. They discuss the challenges of managing a company with different interests at play, including investors and patients. They touch on the potential of AI and the need for regulation and control. David shares his motivation and excitement in achieving his goals and seeing his inventions materialize.

Send us a textIn this episode of the Life Science Success podcast my guest is Robert Bruchet.  Robert is a General Manager - Middle East & Africa at Ethypharm. He applies a deep understanding of commercial levers to maximize the P&L and drive growth. Demonstrated leadership across multiple functions (marketing, sales, market access, and public affairs) and general management. Rob Bruchet discusses his work in the pharmaceutical industry in Africa and the Middle East He talks about the challenges of expanding a business in that region, particularly with established brands and price pressure Bruchet emphasizes the importance of diversity in those markets, noting the wide range of languages and cultures He also shares his experience working in Dubai and the sense of adventure that drove him to move there Bruchet enjoys the opportunity to create something new and make changes in his work, and he is motivated by the drive and ambition of younger people in the industry

Send us a textThe interview discusses challenges faced by at-home diagnostic companies, including differentiation from competitors, market education, and lack of direct billing code. Opportunities for growth in the at-home healthcare market are highlighted, while concerns include the blurring of personal and work life and potential for overcommitment. Exciting developments in technology, particularly in digital health and medtech, are noted as improving quality of life for individuals. Challenges faced include differentiating from competitors, educating the market, and lack of direct billing code for at-home diagnostics Opportunities include growth as at-home healthcare becomes more mainstream Concerns include the blurring of the line between personal and work life and the potential for overcommitment Exciting developments in technology, particularly in the digital health and medtech fields, improving quality of life for individuals

Send us a textIn this episode of the Life Science Success Podcast my guest is Chris Anderson.  Chris is a seasoned Pharmaceutical Professional with more than 20 years of experience in multiple fields within the Industry.   Don Davis and Chris Anderson discuss the regenerative medicine industry Chris highlights the need for partnerships between companies and government entities The challenges of ensuring compliance and patient safety in a new and evolving industry are discussed Chris talks about being inspired by the people and ideas in the industry They both express excitement about the potential for future advancements in regenerative medicine and other areas like AI.

Send us a textIn this episode of the Life Science Success podcast, my guest is Dr. Scott Wagers.  Scott is the CEO of BioSci Consulting, the author of Assembled Chaos, and the host of Beyond Publications podcast. (Consortium Whisperer)   Dr. Scott Wagers helps people develop consortium projects to speed up the realization of the future of medicine. The translational gap is the delay between research findings and clinical implementation, and it takes about 17 years to cross. The bottleneck in the translational gap is the resistance to change and the lack of adoption. AI has the potential to free humans to focus on what they're really optimized for, which is creativity, pattern recognition, and working together. The human mind is optimized for certain things that AI can free us to focus on. Collective thinking of a bunch of different people is a very powerful computer in its own right. Leadership isn't just at the very top level; it's at every level, down to the PhD student who writes an outline or an SOP. Beyond Publications is a podcast about going beyond publications and pushing through the translational gap. Patients inspire Dr. Scott Wagers, and the translational gap concerns him. The dynamic of collective thinking and working together excites Dr. Scott Wagers.